Farah Champsi
CIK 1198321 · last filed 2021-01-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ZSPH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN FRANCISCO, CA 94111
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Population Health Investment Co., Inc. (PHICW) Delisted | Director | — | $0.00 | — | $0 | 1 | 2021-01-26 |
| Kite Pharma, Inc. (KITE) Delisted | Director | 66,074 | — | — | -$64.58M | 8 | 2017-06-22 |
| ZS Pharma, Inc. (ZSPH) Delisted | 10%+ Owner | 2,870,983 | — | — | -$117.94M | 2 | 2015-06-05 |
| TREVENA INC (TRVN) Delisted | Director | 7,024 | $0.01 | $78 | $10.00M | 1 | 2014-12-10 |
| Evofem Biosciences, Inc. (NEOT) Delisted | 10%+ Owner | 432,543 | — | — | $0 | 1 | 2014-12-01 |
| APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | 10%+ Owner | 1,492,200 | $0.39 | $587.3K | $0 | 1 | 2014-11-19 |
| CHIMERIX INC (CMRX) Delisted | Director | 1,714,330 | $8.54 | $14.64M | -$6.94M | 2 | 2013-10-23 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Director | 1,116,214 | — | — | $0 | 1 | 2013-05-30 |
| Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | 10%+ Owner | 165,140 | — | — | $844.9K | 1 | 2011-08-09 |
| CORT | 10%+ Owner | 5,043,299 | $108.49 | $547.15M | $17.60M | 1 | 2008-03-26 |
Recent Filings · Page 2 of 2
20 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-06-05 | ZS Pharma, Inc. (ZSPH) Delisted | Sell (S) | −557,985 | -$31.97M | EDGAR |
| 2015-06-02 | ZS Pharma, Inc. (ZSPH) Delisted | Sell (S) | −1,482,115 | -$85.96M | EDGAR |
| 2014-12-10 | TREVENA INC (TRVN) Delisted | Buy (P) | +2,500,000 | $10.00M | EDGAR |
| 2014-12-01 | Evofem Biosciences, Inc. (NEOT) Delisted | Exer (X) | +468,380 | $4.00M | EDGAR |
| 2014-11-19 | APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | Other (J) | −7,461,000 | $0 | EDGAR |
| 2013-10-23 | CHIMERIX INC (CMRX) Delisted | Sell (S) | −447,499 | -$6.94M | EDGAR |
| 2013-05-30 | PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Conv (C) | +1,218,683 | $0 | EDGAR |
| 2013-04-16 | CHIMERIX INC (CMRX) Delisted | Conv (C) | +2,066,185 | $0 | EDGAR |
| 2011-08-09 | Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | Buy (P) | +67,900 | $844.9K | EDGAR |
| 2008-03-26 | CORT | Buy (P) | +6,354,810 | $17.60M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.